Mirshahi Ahmad, Tadayoni Ramin, Mohsenzadeh Navid, Saeidi Rezvani Talieh, Abrishami Mojtaba
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, University Sorbonne Paris Cité, Paris, France.
J Curr Ophthalmol. 2019 Feb 10;31(2):168-171. doi: 10.1016/j.joco.2019.01.008. eCollection 2019 Jun.
To assess the efficacy of adjuvant topical timolol-dorzolamide with intravitreal bevacizumab (IVB) injection on anatomic and functional results in eyes affected with diabetic macular edema (DME).
In an interventional prospective contralateral pilot eye study at a third level referral academic facility, patients with bilateral DME who were treatment-naive were enrolled. Enrolled patients received a treatment plan of topical timolol-dorzolamide twice daily in the right eye. Three monthly bilateral IVB injections 1.25 mg/0.05 mL were also planned. Baseline central macular thickness (CMT) was measured by spectral-domain optical coherence tomography (SD-OCT), and clinical information such as best corrected visual acuity (BCVA) and intraocular pressure (IOP) were collected at enrollment and one month after the third injection.
Eleven patients (seven females) with DME were included. BCVA and CMT improved in both eyes and IOP decreased in the right eye but did not change in the left eye. In repeated measures ANOVA analysis, the decrease in CMT and improvement in BCVA were significant in the right eye.
Our study suggested that adjuvant topical timolol-dorzolamide in combination with IVB may further reduce central macular thickness in eyes with DME.
评估辅助性局部使用噻吗洛尔-多佐胺联合玻璃体内注射贝伐单抗（IVB）对糖尿病性黄斑水肿（DME）患眼的解剖学和功能学结果的疗效。
在一家三级转诊学术机构进行的一项前瞻性对侧试点眼干预性研究中，纳入初治的双侧DME患者。纳入的患者右眼接受每日两次局部使用噻吗洛尔-多佐胺的治疗方案。还计划每三个月进行一次双侧IVB注射，剂量为1.25 mg/0.05 mL。通过光谱域光学相干断层扫描（SD-OCT）测量基线中心黄斑厚度（CMT），并在入组时和第三次注射后1个月收集最佳矫正视力（BCVA）和眼压（IOP）等临床信息。
纳入11例DME患者（7例女性）。双眼的BCVA和CMT均有所改善，右眼IOP降低，而左眼IOP未改变。在重复测量方差分析中，右眼CMT的降低和BCVA的改善具有显著性。
我们的研究表明，辅助性局部使用噻吗洛尔-多佐胺联合IVB可能进一步降低DME患眼的中心黄斑厚度。
